Latest From BrainCells Inc.
A new life sciences hedge fund operated by two former associates of activist investor Carl Icahn is challenging Otsuka’s takeover of cancer drug developer Astex. Also, Johnson & Johnson’s London Innovation Center announced four alliances, Celgene took another option on one of its investments and Takeda teamed up with New York research institutions to form a new discovery institute.
So long as its research goes as planned, PharmAkea's future is somewhat predictable now that the San Diego-based biopharmaceutical company has entered into a three-year, $35m funding and drug development agreement with Celgene.
Japan's Mitsubishi Tanabe Pharma (MTP) has confirmed that it will spin out and merge its blood plasma fractionation operations with those of the Japanese Red Cross Society later this year.
Oxford BioSciences Jonathan Fleming And Chris Kim On Investing in Korea: An Interview With PharmAsia News (Part 2 of 2)
All eyes are on the Korea-Seoul Life Science Fund to see how the collaboration between the Boston-based venture capital firm Oxford Biosciences, Korea’s Hanwha Venture Capital, the Seoul Metropolitan Government and the Korea Institute for Advancement of Technology under the Ministry of Knowledge Economy will evolve.
- Drug Discovery Tools
- Therapeutic Areas
- Neurology, Nervous System
- North America
- Parent & Subsidiaries
- BrainCells Inc.
- Senior Management
James A Schoeneck, CEO
Alana V McNulty, VP, Fin.
Carrolee Barlow, MD, PhD, CSO & CMO
- Contact Info
Phone: (858) 812-7700
3565 General Atomics Ct.
San Diego, CA 92121
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.